AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GMAB

Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly

Genmab reported a 22% revenue increase in Q3 2026, driven by strong performance of Epkinly and other pipeline assets. The company expects peak sales of over $3B for Epkinly, $2B for Rina-S, and multibillion for pitucentamab. Management expressed confidence in growth despite the Darzalex royalty expiration, citing diversified growth and strong Phase 3 data. Epkinly showed a 47% increase, and the rest of the portfolio grew by 30%.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 7:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The disclosed trial results and sales guidance represent the first public disclosure of these data points, likely influencing Genmab's share price.

02

Market read

First‑time disclosure of robust Phase 3 data and ambitious sales targets could drive Genmab's stock higher and affect peer valuations.

03

What to watch

Potential competition from Polarix R‑CHOP and the need for subcutaneous formulation scale‑up.

Relevance 8/10Novelty 8/10Timing: post‑earnings call today

Background

Genmab presented Q3 2026 earnings call highlights focusing on its three lead oncology assets and upcoming trial readouts.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab's Q3 2026 earnings call disclosed positive Phase 3 data for Epkinly, Rina‑S and pitucentamab, supporting >$3B, >$2B and multibillion peak‑sales estimates.

Expected impact

upward pressure as market prices in higher sales expectations

Evidence & confidence

Executive commentary highlighted robust data, increased revenue trajectory and upcoming approvals, which are fresh material for investors.

Market effects

Sector

Biotech sector may see renewed interest in bispecific antibodies and oncology pipelines.

Regional

European biotech stocks could benefit from Genmab's data as a regional benchmark.

Global

Global oncology investors may re‑price similar late‑stage candidates.

Counterpoint

What could challenge this read

If data maturity concerns persist, the market could discount the upside until regulatory filings.

Key entities

  • Company
    Genmab AS

    Danish biotech firm developing bispecific antibodies.

  • Product
    Epkinly

    Lead bispecific antibody targeting DLBCL.

  • Product
    Rina‑S

    Oncology candidate in platinum‑resistant ovarian cancer.

  • Product
    pitucentamab

    Bispecific antibody in colorectal and head‑neck cancers.

Read at source← All news

StoryGenmab posts 22% nine‑month revenue rise and three positive Phase III readouts, keeps FY‑2026 outlook

Also covered by

5 outlets

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

finance.yahoo.com
$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.

investing.com
$GMABMedAI 8/10

What Genmab A/S (GMAB) Said on Its Q3 Earnings Call

Genmab reported Q3 earnings, highlighting 9% sales growth for TIVDAK to $131M. EPKINLY met its primary endpoint in DLBCL, with a hazard ratio of 0.49. Rina-S and petosemtamab also showed positive trial results. Genmab reaffirmed peak sales estimates and plans for potential filings. The company aims to grow operating profit in 2027 and reduce leverage.

finance.yahoo.com